ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2869

Incorporation of Patient Reported Outcomes Data in the Care of US Veterans with Rheumatoid Arthritis: A Randomized, Controlled Trial

Michael R Bubb1, Reuben Judd1 and Ann D Chauffe2, 1Medicine, Malcom Randall VAMC, Gainesville, FL, 2Rheumatology Clinic of Opelousas, Opelousas, LA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: clinical trials, patient-reported outcome measures and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: 5T108 ACR Abstract: RA–DX, Manifestations, & Outcomes V: Outcomes Measures (2868–2873)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Quantitative disease activity measures are required to implement a treat-to-target algorithm for the treatment of rheumatoid arthritis (RA). Available measures based on patient-derived data have the advantage of ease of use and have been shown to correlate with physician-derived data. While data support the conclusion that the concept of treat-to-target is beneficial to patient outcomes, there is a paucity of data that show that the utilization of any specific disease activity measure improves outcomes. The purpose of this study was to test the hypothesis of whether the addition of the RAPID3 (Routine Assessment Of Patient Index Data 3) patient-reported outcome (PRO) data improves outcomes in RA. Disease activity as measured by DAS28 as well as patient-centric outcomes, including patient reported well-being, patient satisfaction and medication compliance, were measured.

Methods: The intervention design was a single blind, randomized controlled trial of US Veterans with RA. The intervention was to provide PRO data to rheumatologists treating patients in an outpatient setting. PRO data were not provided to physicians for control subjects. All participating physicians attended a lecture series providing education about treat-to-target strategies in RA. Baseline inclusion criteria were patients older than 18 who have had rheumatoid arthritis according to the 1987 ACR revised criteria for RA, and had been seen at least one time previously with diagnosis of RA. Subjects had at least moderate disease activity (DAS28-CRP> 3.2). Trial duration was 12 months. The primary outcome was a change in DAS28. Secondary outcomes included patient satisfaction, percent with minimal clinically important improvement (MCII) in patient global, medication compliance, DAS28, and frequency of achievement of remission criteria (DAS28-CRP<2.3).

Results: The study enrolled 141 subjects with PRO data provided to the treating physician for 71 subjects. Average subject age was 57, 88% were male, and average DAS28 score at entry was 4.01. The average duration of disease was 4.8 years. There were no significant differences in these measures between intervention and control subjects. Data for the primary outcome was available for 108 patients. The DAS28 score decreased to 3.63 ± 0.41 in the intervention group and 3.60 ± 0.43 in the control group. DAS28 remission criteria were met in 4 or 5.6% of intervention subjects and 6 or 8.6% of control subjects. There was a trend to improvement in the MCII for patient global scores in the intervention group.

Conclusion: In this population of US Veterans with relatively advanced RA, the provision of RAPID3 data to rheumatologists who were well-versed in the treat-to-target approach to RA did not significantly improve outcomes.


Disclosure: M. R. Bubb, None; R. Judd, None; A. D. Chauffe, None.

To cite this abstract in AMA style:

Bubb MR, Judd R, Chauffe AD. Incorporation of Patient Reported Outcomes Data in the Care of US Veterans with Rheumatoid Arthritis: A Randomized, Controlled Trial [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/incorporation-of-patient-reported-outcomes-data-in-the-care-of-us-veterans-with-rheumatoid-arthritis-a-randomized-controlled-trial/. Accessed January 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incorporation-of-patient-reported-outcomes-data-in-the-care-of-us-veterans-with-rheumatoid-arthritis-a-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.